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LEVAMISOLE AND 5-FLUOROURACIL have now become the standard che-
motherapeutic regimen for patients with Stage III colon carcinoma. A case of 
multifocal inflammatory leukoencephalopathy secondary to levamisole alone 
or combination of levamisole and 5-fluorouracil is reported. Magnetic reso-
nance imaging with gadolinium demonstrated multifocal contrast-enhancing 
frontal, parietal, occipital, and periventricular white matter lesions. A ster-
eotactic biopsy revealed reactive gliosis and macrophage infiltration, without 
"evidence of metastatic tumor. Despite continuation of 5-fluorouracil, reso-
lution of contrast-enhancing lesions on magnetic resonance imaging without 
further neurological sequelae occurred when levamisole was stopped. The 
patient died with evidence of systemic metastasis 6 months later. Autopsy 
examination of the brain revealed multifocal demyelinating lesions, with no 
evidence of metastatic tumor. Immunoperoxidase studies of demyelinated 
lesions demonstrated infiltrating macrophages strongly positive for Class II 
antigens, interleukin-6, and interleukin-1 a. Surrounding astrocytes were posi-
tive for granulocyte macrophage colony-stimulating factor. Small numbers of 
perivascular T cells were present. This patient represents the first autopsy 
documented case of levamisole associated multifocal inflammatory leukoen-
cephalopathy. (Neurosurgery 35:1138-1143, 1994) 
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Levamisole is a phenylimidothiazole, which was introduced in 1965 as an 
antihelminthic (15). Since then, it has at-
tracted interest as a chemotherapeutic 
agent because of its presumed immuno-
stimulatory activity (9, 25). In conjuction 
with 5-fluorouracil (5-FU), levamisole 
has been shown to decrease the risk of 
clinical recurrence and to increase the 
survival of patients with Stage III colon 
carcinoma (18, 21, 23). Well-documented 
signs and symptoms of levamisole tox-
icity have included diarrhea, reversible 
agranulocytosis, leukopenia, headache, 
confusion, myalgia, and tremor (6, 23, 25, 
31). Recently, four patients with revers-
ible mutifocal inflammatory leukoen-
cephalopathy after treatment with 5-FU 
and levamisole have been reported. The 
authors concluded that the cause was-
most likely secondary to 5-FU; however, 
levamisole toxicity could not be ruled 
out (14, 16). We have recently encoun-
tered another case of multifocal inflam-
matory leukoencephalopathy, which is 
unique in that: 1) multifocal inflamma-
tory leukoencephalopathy seemed to be 
secondary to levamisole alone or a com-
bination of levamisole and 5-FU; 2) au-
topsy findings showed multiple cavitary 
white matter lesions with axonal loss as 
well as demyelination; and 3) immuno-
histochemistry studies suggested that 
the demyelination was associated with 
macrophage activation. 
CASE REPORT 
A 68-year-old right-handed Japanese 
woman underwent primary resection of 
a Stage III colon carcinoma. She was en-
tered into the Southwest Oncology 
Group Protocol 8899 to determine her 
postoperative adjuvant therapy. After 
randomization, she received 450 mg/m2 
of 5-FU i.v. daily for 5 days, followed by 
4 weeks of a 450-mg/m2 5-FU bolus ev-
ery week. Levamisole was given orally 
150 mg daily for 3 days every 2 weeks. It 
was administered concomitantly with 
5-FU for 3 days at the beginning of the 
regimen and every 2 weeks when 5-FU 
was given as a bolus at the beginning of 
the week. Within hours of levamisole ad-
ministration, she complained of feeling 
drunk and confused, lasting for the du-
ration of her levamisole therapy and re-
covering within 24 hours. Levamisole 
was used for 8 weeks; however, it was 
stopped secondary to continued com-
plaints of lethargy, disorientation, ex-
pressive dysphasia, and short-term 
memory loss. 
Ten days after levamisole discontinu-
ation, the patient was subsequently ad-
mitted with progressively poor balance 
and weakness and numbness of her left 
leg. On initial examination, she was afe-
brile, alert, and oriented, but had a mild 
expressive dysphaSia. No cranial nerve 
abnormalities were detected. Motor ex-
amination showed 5-/ 5 strength in her 
left leg, normal elsewhere. Her gait was 
moderately ataxic, with a tendency to fall 
to the right. Sensation was intact to pin 
prick throughout; however, she did have 
a subjective sensation of numbness in 
her left leg. Computed tomography re-
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FIGURE 1. MRI scan (T1-weighted with gadolinium enhancement) shows multiple 
contrast-enhancing frontal, parietal, occipital, and periventricular white matter 
lesions (8) hypo intense to gray matter on T1-weighted images (A) and hyperin-
tense to gray matter on T2-weighted images (C). 
fiGURE 2. MRI scan of corresponding images in Figure 1 shows resolution of 
contrast-enhancing lesions on T1-weighted images on discontinuation of levami-
sole (A and 8). Residual lesions may be seen on T2-weighted images (C). 
vealed multiple contrast-enhancing 
frontal, parietal, occipital, and periven-
tricular intracranial white matter lesions. 
Magnetic resonance imaging (MRI) 
showed multiple enhancing white mat-
~ ter lesions that were hypointense to gray 
matter on Tl-weighted images and hy-
perintense to gray matter on T2-
weighted images (Fig. 1, A-C). Initial dif-
ferential diagnosis included intracranial 
metastasis secondary to primary colon 
adenocarcinoma versus . an infectious 
• cause. Her admitting white blood cell 
Count was 6.3 X 103 cells / mI. Her cere-
brospinal fluid (CSF) cell count was un-
remarkable; CSF protein was 138 mg/ dl, 
and glucose was 58 mg/ dl. Gram stain 
showed 1 + PMNs, 1 + monocytes, and 
no organisms. CSF cytology, bacterial 
cultures, toxoplasmosis titers, and cry to-
coccal titers were negative. CSF oligo-
clonal bands and immunoglobulin G in-
dex were not available. A metastatic 
Workup, including computed tomogra-
phy of the chest and abdomen, showed 
no additional lesions. 
A stereotactic biopsy was performed 
on an enhancing right parietal lesion. 
The biopsy revealed atypical reactive 
gliosis admixed with foamy macro-
phages, suggesting demyelination; how-
ever, no definitive demyelination could 
be documented. Postoperatively, the pa-
tient was placed on dexamethasone (16 
mg/day), which was tapered over 1 
month. Her chemotherapy regimen of 
5-FU and levamisole was discontinued. 
She had a dramatic improvement at 
home, with improvement in her mental 
status and motor strength. Repeat MRI 1 
month later showed resolution of her en-
hancing multifocal white matter lesions 
on Tl-weighted images; however, a few 
residual lesions were seen on T2-
weighted images (Fig. 2, A-C). The pa-
tient again began receiving 5-FU 6 weeks 
after her initial biopsy. At that time, her 
mental status was normal, with a nonfo-
cal neurological examination. Addi-
tional MRI scans of the brain 1 and 4 
months after initiation of 5-FU continued 
to show residual nonenhancing lesions 
on T2-weighted images only. 
The patient died with evidence of 
Widespread systemic metastasis 6 
months later. Neuropathological exami-
nation of the brain revealed multifocal 
demyelinating lesions within the white 
matter of the cerebral hemispheres, in-
cluding the corona radiata, optic radia-
tions, cingulum, and temporal lobe, sev-
eral of which were cavitary, with no 
evidence of metastatic tumor (Fig. 3A). 
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FIGURE 3. Coronal sections ofthe for-
malin-fixed brain show numerous tan-
to-yellow softened areas within the 
white matter of the cerebral hemi-
spheres, including the corona radiata, 
optic radiations, cingulum, and tempo-
rallobe white matter. One of the 
cavitary lesions within the right corona 
radiata is shown (A, arrow). SilVer 
stains of demyelinated lesions show ax-
onal depletion. Note the sparing of 
the U fibers (8, arrow). At higher mag-
nification, residual axons are identi-
fied in the center of a demyelinated le-
sion (C arrowhead). 
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Microscopic examination of the le-
sions demonstrated well-demarcated ar-
eas of extensive gliosis. In the subcortical 
white matter, these areas extended to but 
did not involve the Mynert U fibers (Fig. 
3B). Associated astrocytes were enlarged 
and occasionally bizarre in morphology. 
A myelin stain (Luxol fast blue) of rep-
resentative lesions showed extensive de-
myelination (Fig. 3B). A silver axonal 
stain (modified Bielschowsky) showed 
moderate loss ofaxons, although intact 
axons were identified in the midst of ex-
tensive myelin loss (Fig. 3C). Electron 
microscopy of the lesions showed my-
elin debris, numerous astrocytic pro-
cesses, and rare thinly myelinated axons. 
There was no evidence of active demy-
elination. No viral particles were identi-
fied. 
Immunohistochemical staining was 
performed on cryostat frozen sections of 
brain dissected at autopsy, which con-
tained a demyelinated lesion as previ-
ously described (4). Numerous reactive 
astrocytes (glial fibrillary acidic pro-
tein +, Biogenics, San Ramon, CA), mac-
rophages (CD 11c+, Becton-Dickinson, 
San Jose, CA) (Fig. 4A), and small num-
bers of perivascular T cells (CD 4+ and 
CD 8+, Becton-Dickinson) were present 
in the areas of demyelination. Macro-
phages were strongly positive for Class 
II antigens (Becton-Dickinson) (Fig. 4B), 
interleukin-6 OL-6; Genzyme, Cam-
bridge, MA) (Fig. 4C), and IL-l-a (Gen-
zyme, Cambridge, MA). Tumor necrosis 
factor-a (TNF-a; Genzyme) was very 
weakly positive in macrophages. Reac-
tive astrocytes were strongly positive for 
granulocyte macrophage colony-stimu-
lating factor (Genzyme) (Fig. 40). Im-
munoperoxidase staining for Ki-67 
(Dako, Carpinteria, CA), a proliferation-
associated antigen, demonstrated very 
rare immunoreactive glial nuclei. An im-
munohistochemical stain for the JC virus 
(a kind gift of Dr. Duard Walker, Uni-
versity of Wisconsin, Madison, WI), a 
strain of polyoma virus associated with 
progressive multifocal leukoencephalo-
pathy, showed no reactivity. 
DISCUSSION 
This patient represents a clearly docu-
mented case of multifocal inflammatory 
leukoencephalopathy associated with 
administration of levamisole alone or in 
combination with 5-FU. Unlike the pre-
viously reported cases, our patient had 
selective discontinuation of levamisole 
and continuation of 5-FU, with resolu-
tion clinically and radiographically of 
her intracranial lesions (14, 16). This is 
the first autopsy case of multifocal in-
flammatory leukoencephalopathy, and 
it demonstrates that the demyelinated 
plaques not only have axonal depletion, 
but cavitary changes as well. These cavi-
FIGURE 4. Immunoperoxidase studies of demyelinated lesions reveal scattered in-
filtrating CD 8+ cells within the parenchyma (not shown), as well as numerous 
CD 11 c+ macrophages (A). The macrophages show prominent Class II antigen ex-
pression (B). Numerous macrophages were strongly positive for IL-6 (C) and 
IL-1 a (not shown). TNF-a was only weakly positive in occassional macro phages 
(not shown). Granulocyte macrophage colony-stimulating factor was localized 
prominently to morphologically identifiable astrocytes (D). 
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tary changes, although nonenhancing on 
Tl-weighted images, are seen as residual 
regions of hyperintensity on T2-
weighted images, similar to those re-
ported by Kimmell et al. (16). 
The differential diagnosis of multiple 
intracranial white matter lesions in a pa-
tient such as this is varied. The possiblity 
of metastatic intracranial colon carci-
noma, although unusual without obvi-
ous systemic involvement, must be ruled 
out. Multicentric gliomas, primary cen-
tral nervous system lymphoma, or toxo-
plasmosis must be considered (8, 11, 19, 
20). Progressive multifocalleukoencepa-
thology, although now reported pre-
dominantly in patients with acquired 
immunodeficiency syndrome, also must 
be considered (7). Last, the diagnosis of 
diffuse necrotizing leukoencephalopa-
thy secondary to chemotherapy must be 
considered (27, 28). Intrathecal metho-
trexate or high-dose parenteral metho-
trexate, especially when combined with 
intracranial radiation, has been the most 
widely recognized chemotherapeutic 
agent causing multifocal inflammatory 
leukoencephalopathy (1, 22, 27). Esti-
mated incidence ranges from less than 
1 % to 45%, depending on the mode of 
therapy. Unlike levamisole, symptom 
onset earlier than 3 months after treat-
ment is unusual. 5-FU has been reported 
to cause pancerebellar dysfunction, en-
cephalopathy, and peripheral neuro-
pathy, and derivatives of 5-FU have been 
reported to cause reversible leukoen-
cephalopathies (17, 26, 29). The present 
study suggests that this patient, as well 
as the four previously reported cases 
with multifocal inflammatory leukoen-
cephalopathy, had levamisole-induced 
lesions. No other signs or symptoms of 
levarnisole toxicity, such as agranulocy-
tosis, leukopenia, or severe gastrointes-
tinal problems, were present in this pa-
tient. 
The radiological and pathological 
findings of multifocal inflammatory leu-
koencephalopathy secondary to levami-
sole have been well documented. On 
MRl, the lesions are predominantly su-
pratentorial, periventricular, and en-
hancing after gadolinium administration 
(14). On light and electron microscopy, a 
demyelinating lesion, with axonal pres-
ervation, is seen. Reactive astrocytes, 
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number of lymphocytes, and oligoden-
drocytes at the edge of the demyelinat-
ing lesion are present (14, 16). 
Although the ultrastructural changes 
I of multifocal inflammatory leukoen-
cephalopathy have been reported, the 
mechanism by which levamisole induces 
these lesions is unknown. Levamisole is 
" thought to have an immunorestorative 
effect by increasing antigen response 
and potentiating the functions of lym-
phocytes, macrophages, and granulo-
cytes (30). It increases delayed-type hy-
i persensitivity in humans; however, no 
direct effects on B lymphocytes or anti-
, body production are present (10). In 
mammalian cells, levamisole displays 
both cholinergic and antioxidant prop-
• erties, alters nucleotide levels, and inhib-
its alkaline phosphatase (9). It seems to 
decrease metastasis formation in slowly 
( growing tumors, especially when used 
as an adjuvant to cytoreductive treat-
ment (5). 
To explore the presumed immune-
mediated action of levamisole, immuno-
, histochemical stains for leukocytes and 
cytokines were performed. At the time of 
autopsy, the patient had been neurolog-
ically asymptomatic for approximately 6 
months. The presence of activated leu-
kocyte infiltration with. production of 
proinflammatory cytokines (IL-1a, IL-6, 
and TNF-a) suggests that these lesions, 
j although morphologically quiescent, are 
still immunologically active. TNF-a has 
I been reported to be associated with my-
elin degeneration and astrocytic degen-
'I' eration (13). The finding of only small 
amounts of TNF-a is consistent, there-
fore, with the lack of ongoing demyeli-
nation. The production of granulocyte 
i macrophage colony-stimulating factor 
by reactive astrocytes also may contrib-
ute to the immune response by attracting 
macrophages to the lesion (2). The find-
ing of white matter demyelination asso-
ciated with gliosis, macrophage, and T 
cell infiltration is similar to that found at 
I the periphery of multiple sclerosis 
plaques. Immunohistochemical studies 
of chronic active multiple sclerosis le-
sions have documented the presence of 
activated astrocytes and macrophages, 
With production of Class II, TNF-a, IL-
i 1!l, and IL-2, findings similar to this case 
(]2, 13). Although TNF-a is more promi-
nent in chronic active multiple sclerosis, 
MeT"fl···., }O' 
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we do not know whether TNF-a would 
be more prominent early in the course of 
muItifocal inflammatory leukoencepha-
lopathy. 
Inasmuch as 5-FU and levamisole 
have become the standard postoperative 
adjuvant therapy for patients with Stage 
III carcinoma of the colon, this combina-
tion may be initiated for 25,000 patients 
in the United States in 1993 (3, 23). In a 
patient treated with levamisole present-
ing with focal neurological deficits and 
radiographic evidence of multiple en-
hancing white matter lesions, the possi-
bility of drug-induced leukoencepha-
lopathy must be considered in the 
differential diagnosis. Rapid diagnosis is 
essential, because demyelinating lesions 
potentially develop into permanent le-
sions with axonal depletion and cavitary 
changes. Concomitant administration of 
glucocorticoids may result in more rapid 
clinical and radiographic resolution of 
muItifocal inflammatory leukoencepha-
lopathy (16). 
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COMMENTS 
Because 5-fluorouracil (5-FU) and Le-
vamisole have become standard therapy 
for Stage III colonic carcinoma, one of the 
most frequent forms of cancer, the num-
ber of patients exposed to this drug com-
bination each year is substantial. There-
fore, it is important to raise awareness of 
the possible adverse effects, even if they 
are infrequent. 
The differential diagnosis in a patient 
with cancer and encephalopatic symp-
toms with white matter lesions include a 
wide variety of diseases. Metastases are 
always important considerations, be-
cause they may present in varied forms. 
Direct and indirect effects of treatment 
are also major possibilities. Cranial irra-
diation can produce cerebral lesions 
with involvement of the microvascula-
ture or even large vessels. Chemo-
therapy is another well-known cause of 
white matter disease; the best known ex-
ample is diffuse necrotizing leukoen-
cephalopathy in association with meth-
otrexate, but other agents including 
biological response modifiers (interfer-
ons and interleukins) also can cause 
white matter lesions. Immunosuppres-
sion, related to therapy or to the neo-
plasm itself, predisposes a patient to in-
fectious diseases (e.g., progressive 
multifocal leukoencephalopathy and 
toxoplasmosis) and to tumors such as 
primary central nervous system lym-
phoma. An intriguing form of necrotiz-
ing multifocalleukoencephalopathy has 
been described in association with im-
munosuppression; the pathogenesis is 
unknown, and it is usually confined to 
the basis pontis, although it also may 
involve additionally the white matter of 
the cerebral hemispheres (2). 
Neurotoxicity associated with 5-FU 
has been well described. The most fre-
quent well-defined neurological syn-
drome is pancerebellar dysfunction of 
sudden onset with gait ataxia, appen-
dicular discoordination, dysarthria, and 
nystagmus. More rare are the syndromes 
of encephalopathy (headaches, confu-
sion, disorientation, lethargy, and sei-
zures) and peripheral neuropathy. 5-FU 
derivatives have been implicated in 
cases of encephalopathy with white mat-
ter abnormalities; however, they tend to 
be more diffuse and without evidence of 
inflammation (3). Experimental models 
of 5-FU toxicity implicate metabolites of 
the drug in the production of the lesions: 
a-fluoro J3-alanine seems to be particu-
larly toxic. 
The pathology of these lesions consists 
of vacuolation caused by myelin dysrup-
tion in the cerebellum, brain stem, and 
cerebral white matter; there also may be 
associated necrosis, especially in the 
brain stem, but inflammation is not a 
feature (7). Although most 5-FU is elimi-
nated in the urine unchanged, a small 
percentage (about 10%) is metabolized in 
the liver, and it may generate the toxic 
metabolites. It is reasonable to speculate 
that levamisole might alter the pharma-
cokinetics of 5-FU and increase the pro-
portion that is metabolized by the liver. 
The use of levamisole alone has been 
reported to produce unspecific neuro-
logical symptoms, which include fa-
tigue, taste change, arthralgia/myalgia, 
headaches, dizziness, anxiety, and irri-
tability. Symptoms usually improve 
after drug administration is discontin-
ued (6). Chen et al. contribute with the 
description of a new case of inflamma-
tory multifocalleukoencephalopathy as-
sociated with this therapy. They present 
the first autopsy study of this disease 
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and suggest that pathogenesis would be 
related more to Levamisole rather than 
to 5-FU. 
It is possible that this syndrome is 
more frequent than is apparent, because 
subclinical forms of milder disease may 
be unnoticed. Neurological symptoms 
have been described in about 18% of pa-
tients treated with this drug combina-
tion; most of them were vague, mild, and 
resolved spontaneously after ceasing 
therapy (6). It is conceivable that at least 
some of these cases, if studied with mag-
netic resonance imaging, may have had 
lesions similar to the ones described in 
this and in previous papers (4, 5). 
Leukoencephalopathy associated with 
chemotherapy has been well described. 
It has been related mostly, but not ex-
clusively, to methotrexate, especially 
when combined with brain radiation (8). 
However, this diffuse necrotizing leu-
koencephalopathy is a different entity to 
the one described by Chen et al., which 
is an inflammatory demyelinating leu-
koencephalopathy. Although they may 
look radiologically similar because of a 
similar pattern of lesion distribution, dif-
fuse necrotizing leukoencephalopathy is 
characterized by necrosis and swelling 
ofaxons, with inconsistent spatial rela-
tionship to blood vessels and very little 
evidence of inflammation. In contrast, 
the disease discussed here is a perivas-
cular inflammatory process, with promi-
nent demyelination and some degree of 
axonal disruption ofaxons. Histopathol-
ogy and immunohistochemistry are 
reminiscent of the findings described in 
multiple sclerosis (1). This is intriguing, 
considering that the syndrome could be 
caused by the levamisole component of 
the chemotherapy. Levamisole has well-
described immunomodulatory stimu-
lant effects. In vivo human studies have 
founded increased dinitrochloroben-
zene skin test reactivity, increased lym-
phocyte proliferation to mitogens, and 
increased expression of neutrophil Fc re-
ceptors (9). An interesting possibility 
would be the application of the use of 
levamisole to develop a more adequate 
animal model to further understand 
multiple sclerosis. The role of steroids in 
the treatment of levamisole- and 5-FU-
associated leukoencephalopathy is un-
certain, because most cases have re-
ceived steroids; however, one patient 
4 -r .-
who did not receive treatment presented 
clinical and radiological improvement as 
well. 
Raul F. Valenzuela 
Fred H. Hochberg 
Boston, Massachusetts 
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In patients with known cancer, the 
presence of a single supratentorial en-
hancing mass lesion has approximately a 
90% probability of representing a metas-
tasis (1). This probability is expectedly 




This report describes an unusual oc-
currence of leukoencephalopathy, pre-
sumably caused by levamisole (but not 
necessarily so), and the presence of mul-
tiple lesions on magnetic resonance im-
aging that can and should be considered 
metastatic in nature until proved other-
wise. The systematic use of whole-brain 
radiation therapy without biopsy in such 
patients is unfortunately not rare, and 
this example again emphasizes the ad-
vantages and simplicity of stereotactic 
biopsies in providing the necessary in-
formation for optimal therapeutic deci-
sion making. The authors' excellent fol-
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